The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization
Abstract
The discovery, development, and use of biomarkers for a variety of drug development purposes are areas of tremendous interest and need. Biomarkers can become accepted for use through submission of biomarker data during the drug approval process. Another emerging pathway for acceptance of biomarkers is via the biomarker qualification program developed by the Center for Drug Evaluation and Research (CDER, US Food and Drug Administration). Evidentiary standards are needed to develop and evaluate various types of biomarkers for their intended use and multiple stakeholders, including academia, industry, government, and consortia must work together to help develop this evidence. The article describes various types of biomarkers that can be useful in drug development and evidentiary considerations that are important for qualification. A path forward for coordinating efforts to identify and explore needed biomarkers is proposed for consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Power failure: why small sample size undermines the reliability of neuroscience
Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3475 · Cited by 7,641
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702 · cited 2×
“This factor is especially important when published data are selected since only 20–25% data have been reported to be reproducible.(5) Also, there seems to be a consensus that reproducibility is a concern in science.”
BackgroundBelieve it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Policy: NIH plans to enhance reproducibility
Collins, F. S., & Tabak, L. A. (2014) · Nature · doi:10.1038/505612a · Cited by 1,247
The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs
Murray, J. S., Elashoff, M. R., Iacono-Connors, L. C., Cvetkovich, T. A., & Struble, K. A. (1999) · AIDS · doi:10.1097/00002030-199905070-00008 · Cited by 174
Cited by
Machine Learning Approaches for Clinical Psychology and Psychiatry
Dwyer, D. B., Falkai, P., & Koutsouleris, N. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045037 · Cited by 966
Wearable devices in clinical trials: hype and hypothesis
Izmailova, E. S., Wagner, J. A., & Perakslis, E. D. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.966 · Cited by 265
Black, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Speech as a Biomarker: Opportunities, Interpretability, and Challenges
Ramanarayanan, V., Lammert, A. C., Rowe, H. P., Quatieri, T. F., & Green, J. R. (2022) · Perspectives of the ASHA Special Interest Groups · doi:10.1044/2021_persp-21-00174 · Cited by 70
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
Metadata
- Authors
- Amur, S., LaVange, L., Zineh, I., Buckman‐Garner, S., & Woodcock, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-06-06
- Volume
- 98
- Issue
- 1
- Pages
- 34-46
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2107153099
- Cited by
- 211
- References
- 6
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. https://app.cochat.ai/papers/10.1002/cpt.136
- The paper
- Amur, S., LaVange, L., Zineh, I., Buckman‐Garner, S., & Woodcock, J. (2015). Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.